Government to sign off on CF drug deal next month
Negotiations between HSE and manufacturer Vertex over the drug's price enter final phase
The government expects to sign off on the purchase of life-changing cystic fibrosis drug Orkambi next month.
Protracted negotiations between the HSE and manufacturer Vertex over the price of the drug have entered the final phase, with a ten-year deal that encompasses other cystic fibrosis treatments like Kalydeco envisaged.
The exact price the state will pay for Orkambi is unclear, but it will be lower than the €159,000 per patient, per year rejected by the...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Nadine O’Regan: Fishing for compliments at our own funerals
Jaws it ain’t, but a brush with an angry weever fish in the shallows of the Atlantic Ocean prompts some musings on mortality
Emer McLysaght: Take it or leave it, Father’s Day is not an issue
We don’t have to ban Father’s Day, we just have to realise it’s not for everyone and allow people to choose whether or not to celebrate
Analysis: Moral hazard at the heart of public health leaders’ reluctance to begin use of rapid antigen testing
Rapid tests may be useful in certain situations, but it’s all about the context in which they are deployed
Elaine Byrne: What structural defect means taxpayers always carry the can?
The homeowners in the mica scandal must be compensated, but the taxpayer deserves some consideration too